AI Article Synopsis

Article Abstract

'Intact' parathyroid hormone (iPTH) assays are used to measure serum PTH levels in haemodialysis patients to diagnose and monitor secondary hyperparathyroidism and consequent renal osteodystrophy (ROD); these assays exhibit cross-reactivity with long carboxyl-terminal PTH fragments (C-PTH) that accumulate in end stage renal failure (ESRF) and antagonise the biological activity of the whole molecule, 1-84 PTH. The effects of haemodialysis on C-PTH are not known. We investigated how haemodialysis affects serum concentrations of calcium, iPTH, 1-84 PTH, C-PTH, and other markers of bone turnover; bone-specific alkaline phosphatase (BALP) and type 1 collagen cross-linked telopeptide (CTx). Fifteen patients, mean (range) age 13.9 (4.3-17.6) years, haemodialysed for a median of 16.3 (4-41) months, had pre- and post-dialysis serum samples collected for routine biochemistry, BALP, CTx, iPTH and 1-84 PTH assays. Changes to serum concentrations and relationships between these biochemical surrogate markers of ROD were investigated. Serum phosphate and PTH levels (measured by both assays) fell significantly during dialysis, whereas serum calcium, C-PTH, the 1-84 PTH: C-PTH ratio and BALP and CTx concentrations were not significantly changed. 1-84 PTH levels were related to pre but not post dialysis serum calcium levels and changes to 1-84 PTH levels during dialysis were related to changes in serum calcium levels. 1-84 PTH and iPTH were reduced by haemodialysis, whereas levels of BALP and CTx remained stable post-dialysis. The relationship between BALP and CTx and bone histology requires investigation to determine whether they are more useful markers of bone turnover in this patient group.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-006-0378-xDOI Listing

Publication Analysis

Top Keywords

1-84 pth
28
pth levels
16
balp ctx
16
markers bone
12
bone turnover
12
serum calcium
12
pth
10
serum
8
serum concentrations
8
ipth 1-84
8

Similar Publications

Article Synopsis
  • The aim was to determine whether continuous or multiple daily doses of PTH would be more effective in reducing urinary calcium excretion and lowering the nephrolithiasis risk, using a pharmacokinetic-pharmacodynamic (PKPD) model.
  • The results indicated that continuous PTH infusion significantly improved phosphate clearance, although its effect on calcium clearance was less pronounced, suggesting that further research on continuous administration is warranted.
View Article and Find Full Text PDF
Article Synopsis
  • Vitamin D plays a role in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), particularly affecting secondary hyperparathyroidism in hemodialysis (HD) patients, and while cholecalciferol is recommended for vitamin D deficiency, its effects on CKD-MBD are not entirely clear.
  • An observational study involved 22 HD patients with vitamin D levels between 30-50 ng/mL receiving cholecalciferol to boost their levels above 75 ng/mL, comparing baseline biochemical markers with those at higher vitamin D levels.
  • The study found that 73% of participants achieved the target vitamin D level in about 7.5 weeks with a total dose of 525,000
View Article and Find Full Text PDF

PTH immunoassay interference: differential diagnosis with normocalcemic primary hyperparathyroidism?

Arch Endocrinol Metab

November 2024

Universidade Federal de São Paulo Escola Paulista de Medicina Departamento de Endocrinologia e Metabolismo São PauloSP Brasil Departamento de Endocrinologia e Metabolismo, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil.

The main diagnostic dilemma in normocalcemic hyperparathyroidism is differentiating this condition from secondary hyperparathyroidism and other causes of elevated parathyroid hormone (PTH) levels in eucalcemic patients, including potential assay interferences. Despite the analytical sensitivity of immunoassays, they may lack adequate accuracy due to several analytical interferences, such as the presence of heterophilic antibodies. Immunoassays for PTH measurement use the immunometric "sandwich" technique, and only a few cases of interference with this assay have been reported to date.

View Article and Find Full Text PDF

Hypoparathyroidism: an update on new therapeutic approaches.

Endocrine

October 2024

Department of Pediatrics, IRCCS Ospedale San Raffaele, Milano, Italy.

Background: Hypoparathyroidism is a rare endocrine disease characterized by insufficient parathyroid hormone (PTH) secretion by the parathyroid glands, leading to hypocalcemia. In contrast to most hormone deficiencies for which hormone replacement is currently the mainstay of therapy, hypoparathyroidism has conventionally been treated with calcium supplements and active analogs of vitamin D. Although the advent of a replacement therapy with 1-34 and 1-84 PTH represented a major step in the therapeutic history of hypoparathyroidism, several new molecules and different management strategies have recently been developed.

View Article and Find Full Text PDF

Introduction: Receptor activity-modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G-protein-coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. This study investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTH and PTH-related protein (PTHrP)-derived ligands.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!